What is the difference between Vesilute and Chitomur?

Both target bladder tissue, but Vesilute is a synthetic single dipeptide (Glu-Asp), while Chitomur is a natural peptide complex extracted from animal bladder tissue. Chitomur contains a broader mix of peptides and has more clinical data. Vesilute is the simplified, synthetic counterpart in Khavinson's system.

How does Vesilute differ from larger peptides like BPC-157?

Vesilute is a dipeptide (just two amino acids) that is proposed to penetrate cell membranes and interact directly with DNA in the nucleus. Larger peptides like BPC-157 primarily work through cell-surface receptor signaling. This gives them fundamentally different mechanisms of action.

Is Vesilute FDA-approved?

No. Vesilute is not FDA-approved and is not used in mainstream Western medicine. Most clinical data comes from Russian research institutions associated with the Khavinson bioregulator program.

Vesilute

A synthetic dipeptide bioregulator (Glu-Asp) from the Khavinson system, studied for bladder function support, urinary health, and age-related urogenital decline.

PreliminaryLimited Data

What is Vesilute?

Vesilute is a synthetic dipeptide consisting of glutamic acid and aspartic acid (Glu-Asp), developed as part of Vladimir Khavinson's bioregulator peptide system. It is classified as a Cytogen — a lab-synthesized short peptide designed to mirror the regulatory effects of peptides naturally found in bladder tissue. Its natural-extract counterpart is Chitomur. Khavinson's bioregulator research spans over 40 years, with short peptides like Vesilute proposed to interact directly with DNA to modulate gene expression in target tissues.

Why People Talk About It

Age-related bladder dysfunction and overactive bladder

Preliminary

Urinary frequency and nocturia reduction

Preliminary

Prostate health support in aging men

Preliminary

Epigenetic gene regulation in bladder tissue

Limited

How It Works

Vesilute is a tiny two-amino-acid peptide proposed to enter cells and reach the nucleus, where it may interact with DNA to reactivate genes involved in bladder tissue maintenance. As we age, some of these genes become silenced — Vesilute is thought to help reverse that process in bladder and urinary tract tissue.

Common Questions

Safety Information

Important Safety Notes

Common Side Effects

Generally well-tolerated in available studiesMild injection site irritation (injectable form)Transient mild digestive upset (oral form)

Cautions

• Not FDA-approved
• Clinical data is limited and primarily from Russian research
• Quality and purity vary significantly by source
• Should be used under clinician guidance

What We Don't Know

Western clinical trial data is absent. Most evidence comes from the Khavinson research program. Long-term safety of chronic use has not been evaluated in controlled Western studies. The claimed mechanism of direct DNA interaction by a dipeptide remains debated.

Published Research

6 studies

Peptide Regulation of Gene Expression: A Systematic Review.

ReviewPMID: 34834147

Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides.

PreclinicalPMID: 32399807

Peptide Regulation of Cell Differentiation.

ReviewPMID: 31808038

Correction of age related bladder function decrease with peptide geroprotector in women.

Randomized Controlled TrialPMID: 28976156

Short Peptides Regulate Gene Expression.

ReviewPMID: 27909961

Peptide geroprotector application for treatment of elderly and senile patients with prostatic hyperplasia.

Randomized Controlled TrialPMID: 24640697

Mechanism of Action

Vesilute (Glu-Asp) is proposed to bypass cell-surface receptors due to its small molecular size, penetrating both cytoplasmic and nuclear membranes to interact directly with DNA and histone proteins. Research from the Khavinson group suggests it binds to AT-rich DNA sequences (particularly ATTT motifs) in regulatory regions of bladder-related genes, promoting chromatin decondensation — shifting heterochromatin toward euchromatin — and reactivating age-silenced gene expression. It is also proposed to inhibit glycogen aggregation in bladder smooth muscle, reducing excessive detrusor contractions. Broader Khavinson research on short peptides (2-7 amino acids) has demonstrated nuclear penetration and nucleosome binding in vitro, though the tissue-specificity mechanism for Vesilute remains incompletely characterized.

Evidence Snapshot

Overall Confidence25%

Human Clinical Evidence

Very limited for Vesilute specifically. The most relevant human data is for Chitomur (its natural-extract counterpart): a randomized study in 31 women with overactive bladder showed a 38% decrease in urgency episodes and 43% decrease in incontinence episodes (PMID: 28976156), and a study in 28 men with BPH showed improved urination parameters (PMID: 24640697). Direct clinical trials on the synthetic Vesilute dipeptide are not indexed in PubMed.

Animal / Preclinical

Limited direct data for Vesilute. The broader Khavinson short-peptide research program provides supportive preclinical evidence: studies demonstrate that short peptides penetrate cell nuclei and bind DNA (PMID: 27909961), modulate gene expression in aging mesenchymal stem cells (PMID: 32399807), and regulate cell differentiation through epigenetic mechanisms (PMID: 31808038).

Mechanistic Rationale

Moderate within the Khavinson framework. The proposed mechanism of direct DNA interaction by short peptides has been demonstrated in vitro for the broader class. However, the tissue-specific targeting to bladder cells and the ATTT-motif binding specificity have not been independently replicated outside the originating research group.

Forms & Administration

Vesilute is available in capsule, sublingual, and injectable formats. Capsule protocols typically involve 2 capsules daily for 10-30 days. Injectable protocols use 10-20 mg per week subcutaneously. All peptides should only be used under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.

Use Cases & Evidence Levels

Age-related bladder dysfunction and overactive bladder

Preliminary30%

Urinary frequency and nocturia reduction

Preliminary30%

Prostate health support in aging men

Preliminary30%

Epigenetic gene regulation in bladder tissue

Limited15%

Safety Profile

Safety Information

Common Side Effects

Generally well-tolerated in available studiesMild injection site irritation (injectable form)Transient mild digestive upset (oral form)

Cautions

• Not FDA-approved
• Clinical data is limited and primarily from Russian research
• Quality and purity vary significantly by source
• Should be used under clinician guidance

What We Don't Know

Published Research

6 studies

Peptide Regulation of Gene Expression: A Systematic Review.

ReviewPMID: 34834147

Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides.

PreclinicalPMID: 32399807

Peptide Regulation of Cell Differentiation.

ReviewPMID: 31808038

Correction of age related bladder function decrease with peptide geroprotector in women.

Randomized Controlled TrialPMID: 28976156

Short Peptides Regulate Gene Expression.

ReviewPMID: 27909961

Peptide geroprotector application for treatment of elderly and senile patients with prostatic hyperplasia.

Randomized Controlled TrialPMID: 24640697

All references link directly to PubMed. Citations are selected by clinicians for relevance and quality.

Related Peptides

Epithalon

Preliminary

A synthetic tetrapeptide studied for its potential to activate telomerase and influence cellular aging.

Thymalin

Moderate

A thymic peptide complex studied for immune system restoration, particularly in aging populations and immunocompromised states.

Pinealon

PreliminaryBeginner

A short tripeptide studied for neuroprotective and cognitive-enhancing properties, part of the Khavinson peptide bioregulator family.

Cortagen

Preliminary

A synthetic peptide bioregulator targeting brain cortex function, studied for cognitive enhancement and neuroprotection in aging.

Vesugen

Preliminary

A synthetic tripeptide bioregulator (Lys-Glu-Asp) from the Khavinson system, studied for vascular protection, endothelial function, and age-related cardiovascular decline.

Quick Facts

Class: Bioregulator Peptide
Evidence: Preliminary
Safety: Limited Data
Updated: Apr 2026
Citations: 6PubMed

Also known as

Glu-AspED DipeptideBladder Bioregulator

Evidence Score

Overall Confidence25%

Clinical Trials

View Clinical Trials

Links to ClinicalTrials.gov for reference. Listing does not imply endorsement.